Cargando…

Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis

Nowadays, the alarming rise in multidrug-resistant microorganisms urgently demands for suitable alternatives to current antibiotics. In this regard, antimicrobial peptides (AMPs) have received growing interest due to their broad spectrum of activities, potent antimicrobial properties, unique mechani...

Descripción completa

Detalles Bibliográficos
Autores principales: Piras, Anna M., Maisetta, Giuseppantonio, Sandreschi, Stefania, Gazzarri, Matteo, Bartoli, Cristina, Grassi, Lucia, Esin, Semih, Chiellini, Federica, Batoni, Giovanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412066/
https://www.ncbi.nlm.nih.gov/pubmed/25972852
http://dx.doi.org/10.3389/fmicb.2015.00372
_version_ 1782368597946925056
author Piras, Anna M.
Maisetta, Giuseppantonio
Sandreschi, Stefania
Gazzarri, Matteo
Bartoli, Cristina
Grassi, Lucia
Esin, Semih
Chiellini, Federica
Batoni, Giovanna
author_facet Piras, Anna M.
Maisetta, Giuseppantonio
Sandreschi, Stefania
Gazzarri, Matteo
Bartoli, Cristina
Grassi, Lucia
Esin, Semih
Chiellini, Federica
Batoni, Giovanna
author_sort Piras, Anna M.
collection PubMed
description Nowadays, the alarming rise in multidrug-resistant microorganisms urgently demands for suitable alternatives to current antibiotics. In this regard, antimicrobial peptides (AMPs) have received growing interest due to their broad spectrum of activities, potent antimicrobial properties, unique mechanisms of action, and low tendency to induce resistance. However, their pharmaceutical development is hampered by potential toxicity, relatively low stability and manufacturing costs. In the present study, we tested the hypothesis that the encapsulation of the frog-skin derived AMP temporin B (TB) into chitosan nanoparticles (CS-NPs) could increase peptide’s antibacterial activity, while reducing its toxic potential. TB-loaded CS-NPs with good dimensional features were prepared, based on the ionotropic gelation between CS and sodium tripolyphosphate. The encapsulation efficiency of TB in the formulation was up to 75%. Release kinetic studies highlighted a linear release of the peptide from the nanocarrier, in the adopted experimental conditions. Interestingly, the encapsulation of TB in CS-NPs demonstrated to reduce significantly the peptide’s cytotoxicity against mammalian cells. Additionally, the nanocarrier evidenced a sustained antibacterial action against various strains of Staphylococcus epidermidis for at least 4 days, with up to 4-log reduction in the number of viable bacteria compared to plain CS-NPs at the end of the observational period. Of note, the antimicrobial evaluation tests demonstrated that while the intrinsic antimicrobial activity of CS ensured a “burst” effect, the gradual release of TB further reduced the viable bacterial count, preventing the regrowth of the residual cells and ensuring a long-lasting antibacterial effect. The developed nanocarrier is eligible for the administration of several AMPs of therapeutic interest with physical–chemical characteristics analog to those of TB.
format Online
Article
Text
id pubmed-4412066
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44120662015-05-13 Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis Piras, Anna M. Maisetta, Giuseppantonio Sandreschi, Stefania Gazzarri, Matteo Bartoli, Cristina Grassi, Lucia Esin, Semih Chiellini, Federica Batoni, Giovanna Front Microbiol Microbiology Nowadays, the alarming rise in multidrug-resistant microorganisms urgently demands for suitable alternatives to current antibiotics. In this regard, antimicrobial peptides (AMPs) have received growing interest due to their broad spectrum of activities, potent antimicrobial properties, unique mechanisms of action, and low tendency to induce resistance. However, their pharmaceutical development is hampered by potential toxicity, relatively low stability and manufacturing costs. In the present study, we tested the hypothesis that the encapsulation of the frog-skin derived AMP temporin B (TB) into chitosan nanoparticles (CS-NPs) could increase peptide’s antibacterial activity, while reducing its toxic potential. TB-loaded CS-NPs with good dimensional features were prepared, based on the ionotropic gelation between CS and sodium tripolyphosphate. The encapsulation efficiency of TB in the formulation was up to 75%. Release kinetic studies highlighted a linear release of the peptide from the nanocarrier, in the adopted experimental conditions. Interestingly, the encapsulation of TB in CS-NPs demonstrated to reduce significantly the peptide’s cytotoxicity against mammalian cells. Additionally, the nanocarrier evidenced a sustained antibacterial action against various strains of Staphylococcus epidermidis for at least 4 days, with up to 4-log reduction in the number of viable bacteria compared to plain CS-NPs at the end of the observational period. Of note, the antimicrobial evaluation tests demonstrated that while the intrinsic antimicrobial activity of CS ensured a “burst” effect, the gradual release of TB further reduced the viable bacterial count, preventing the regrowth of the residual cells and ensuring a long-lasting antibacterial effect. The developed nanocarrier is eligible for the administration of several AMPs of therapeutic interest with physical–chemical characteristics analog to those of TB. Frontiers Media S.A. 2015-04-28 /pmc/articles/PMC4412066/ /pubmed/25972852 http://dx.doi.org/10.3389/fmicb.2015.00372 Text en Copyright © 2015 Piras, Maisetta, Sandreschi, Gazzarri, Bartoli, Grassi, Esin, Chiellini and Batoni. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Microbiology
Piras, Anna M.
Maisetta, Giuseppantonio
Sandreschi, Stefania
Gazzarri, Matteo
Bartoli, Cristina
Grassi, Lucia
Esin, Semih
Chiellini, Federica
Batoni, Giovanna
Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis
title Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis
title_full Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis
title_fullStr Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis
title_full_unstemmed Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis
title_short Chitosan nanoparticles loaded with the antimicrobial peptide temporin B exert a long-term antibacterial activity in vitro against clinical isolates of Staphylococcus epidermidis
title_sort chitosan nanoparticles loaded with the antimicrobial peptide temporin b exert a long-term antibacterial activity in vitro against clinical isolates of staphylococcus epidermidis
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412066/
https://www.ncbi.nlm.nih.gov/pubmed/25972852
http://dx.doi.org/10.3389/fmicb.2015.00372
work_keys_str_mv AT pirasannam chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT maisettagiuseppantonio chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT sandreschistefania chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT gazzarrimatteo chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT bartolicristina chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT grassilucia chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT esinsemih chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT chiellinifederica chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis
AT batonigiovanna chitosannanoparticlesloadedwiththeantimicrobialpeptidetemporinbexertalongtermantibacterialactivityinvitroagainstclinicalisolatesofstaphylococcusepidermidis